New Lipid Lowering Therapies for Cardiovascular and Metabolic Diseases: Lessons from the Past and Future Challenges

118 Pages·2019·9.707 MB·English

by  Ahmed Bakillah (editor)

New Lipid Lowering
Therapies for
Cardiovascular and
Metabolic Diseases
Lessons from the Past and
Future Challenges
Edited by
Ahmed Bakillah
Printed Edition of the Special Issue Published in Diseases
www.mdpi.com/journal/diseases
New Lipid Lowering Therapies

for Cardiovascular and

Metabolic Diseases

New Lipid Lowering Therapies

for Cardiovascular and Metabolic

Diseases: Lessons from the Past

and Future Challenges
SpecialIssueEditor
AhmedBakillah
MDPI•Basel•Beijing•Wuhan•Barcelona•Belgrade
SpecialIssueEditor
AhmedBakillah
KingAbdullahInternationalMedical
ResearchCenter(KAIMRC)
SaudiArabia
EditorialOffice
MDPI
St.Alban-Anlage66
4052Basel,Switzerland
ThisisareprintofarticlesfromtheSpecialIssuepublishedonlineintheopenaccessjournalDiseases
(ISSN2079-9721)from2017to2019(availableat:https://www.mdpi.com/journal/diseases/special
issues/therapiesCVD)
Forcitationpurposes,citeeacharticleindependentlyasindicatedonthearticlepageonlineandas
indicatedbelow:
LastName, A.A.; LastName, B.B.; LastName, C.C.ArticleTitle. JournalNameYear, ArticleNumber,
PageRange.
ISBN 978-3-03921-676-5 (Pbk)
ISBN 978-3-03921-677-2 (PDF)
(cid:2)c 2019bytheauthors. ArticlesinthisbookareOpenAccessanddistributedundertheCreative
Commons Attribution (CC BY) license, which allows users to download, copy and build upon
publishedarticles,aslongastheauthorandpublisherareproperlycredited,whichensuresmaximum
disseminationandawiderimpactofourpublications.
ThebookasawholeisdistributedbyMDPIunderthetermsandconditionsoftheCreativeCommons
licenseCCBY-NC-ND.
Contents
AbouttheSpecialIssueEditor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . vii
Preface to ”New Lipid Lowering Therapies for Cardiovascular and Metabolic Diseases:
LessonsfromthePastandFutureChallenges”. . . . . . . . . . . . . . . . . . . . . . . . . . . . . ix
TheodosiosD.Filippatos,AnastaziaKeiandMosesS.Elisaf
Anacetrapib,aNewCETPInhibitor:TheNewToolfortheManagementofDyslipidemias?
Reprintedfrom:diseases2017,5,21,doi:10.3390/diseases5040021. . . . . . . . . . . . . . . . . . . 1
HayderM.Al-kuraishy,AliI.Al-GareebandAliK.Al-Buhadilly
RosuvastatinImprovesVaspinSerumLevelsinObesePatientswithAcuteCoronarySyndrome
Reprintedfrom:diseases2018,6,9,doi:10.3390/diseases6010009 . . . . . . . . . . . . . . . . . . . 9
Dimitrios Siskos and Konstantinos Tziomalos
The Role of Statins in the Management of Patients Undergoing Coronary Artery
Bypass Grafting
Reprintedfrom:diseases2018,6,102,doi:10.3390/diseases6040102 . . . . . . . . . . . . . . . . . . 19
Ismael San Mauro Martı´n, Javier Andre´s Blumenfeld Olivares, Eva Pe´rez Arruche,
Esperanza Arce Delgado, Mar´ıa Jose´ Ciudad Caba n˜as, Elena Garicano Vilar and Luis
Collado Yurrita
Genomic Influence in the Prevention of Cardiovascular Diseases with a Sterol-Based Treatment
Reprintedfrom:diseases2018,6,24,doi:10.3390/diseases6020024. . . . . . . . . . . . . . . . . . . 23
Umair Iqbal, Brandon J. Perumpail, Nimy John, Sandy Sallam, Neha D. Shah,
Waiyee Kwong, George Cholankeril, Donghee Kim and Aijaz Ahmed
Judicious Use of Lipid Lowering Agents in the Management of NAFLD
Reprinted from: diseases 2018, 6, 87, doi:10.3390/diseases6040087 . . . . . . . . . . . . . . . . . . . 35
Constantine E. Kosmas, Alba Mu n˜oz Estrella, Andreas Sourlas, Delia Silverio,
Elizabeth Hilario, Peter D. Montan and Eliscer Guzman
Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia
Reprinted from: diseases 2018, 6, 63, doi:10.3390/diseases6030063 . . . . . . . . . . . . . . . . . . . 45
Christian Abendstein Kjellmo, Anders Hovland and Knut Tore Lappega˚rd
CVD Risk Stratification in the PCSK9 Era: Is There a Role for LDL Subfractions?
Reprinted from: diseases 2018, 6, 45, doi:10.3390/diseases6020045 . . . . . . . . . . . . . . . . . . . 51
Kazutoshi Sugiyama and Yoshifumi Saisho
Management of Dyslipidemia in Type 2 Diabetes: Recent Advances in Nonstatin Treatment
Reprinted from: diseases 2018, 6, 44, doi:10.3390/diseases6020044 . . . . . . . . . . . . . . . . . . . 62
Giovanni Ciccarelli, Saverio D’Elia, Michele De Paulis, Paolo Golino and
Giovanni Cimmino
Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9
Monoclonal Antibodies
Reprinted from: diseases 2018, 6, 22, doi:10.3390/diseases6010022 . . . . . . . . . . . . . . . . . . . 75
Mohamed Zaiou and Ahmed Bakillah
Epigenetic Regulation of ATP-Binding Cassette Protein A1 (ABCA1) Gene Expression: A New
Era to Alleviate Atherosclerotic Cardiovascular Disease
Reprintedfrom:diseases2018,6,34,doi:10.3390/diseases6020034. . . . . . . . . . . . . . . . . . . 92
v
Zainab Jahangir, Ahmed Bakillah and Jahangir Iqbal
Regulation of Sphingolipid Metabolism by MicroRNAs: A Potential Approach to
Alleviate Atherosclerosis
Reprintedfrom:diseases2018,6,82,doi:10.3390/diseases6030082. . . . . . . . . . . . . . . . . . . 97
vi
About the Special Issue Editor
Ahmed Bakillah Research Scientist and Head of the Research Training & Development Section
at King Abdullah International Medical Research Center (KAIMRC), Eastern Region- Al Ahsa,
Saudi Arabia. Prior to joining KAIMRC, Dr. Bakillah was an Assistant Professor in the
DepartmentofMedicineatSUNYDownstateMedicalCenter, Brooklyn, NY,USA.Healsoserved
asResearchDirectorfortheEmpireClinicalResearchInvestigatorProgram(ECRIP).Dr. Bakillah
completedhisPh.D.atReneDescartesUniversityofParis,France,andperformedhispostdoctoral
fellowship at the Medical College of Pennsylvania, Philadelphia, PA, USA. His research interests
lie in the area of cardiovascular diseases with a focus on lipids and lipoprotein abnormalities
in diabetes, obesity, and atherosclerosis. Dr. Bakillah worked for almost a decade at two
major pharmaceutical companies (Novo Nordisk A/S, Denmark and GlaxoSmithKline, USA).
Dr. Bakillah has served for about ten years as the Managing Editor for the journal Nutrition
& Metabolism. He currently serves as an ad-hoc reviewer and member of the Editorial Board
in several peer-reviewed journals. Dr. Bakillah also served as Guest Editor for special issues
of Frontiers in Bioscience (http://www.bioscience.org/special-issue-details?editorid=1714) and
Diseases (https://www.mdpi.com/journal/diseases/specialissues/therapiesCVD). Dr. Bakillah
has published numerous scientific papers in highly impacted journals, and his work has been
supportedbyintra-andextramuralgrantsfromvariousagenciesinEuropeandtheUSA
vii

Preface to ”New Lipid Lowering Therapies for
Cardiovascular and Metabolic Diseases: Lessons from
the Past and Future Challenges”
Thisbookillustratessomeofthemostrecentresearcheffortsthathavebeenmadeinlowering
plasmacholesterollevelsinpatientswithCVD.Selectedarticlesaimedtoilluminateadvancesand
urgentchallengesinthemanagementofCVD,includingdiseasemanagementusingstatin-combined
therapeuticstrategies.
AhmedBakillah
SpecialIssueEditor
ix